Clinical trials: Patients With Prostate Cancer
Fatigue, Metastatic Prostate Carcinoma
Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients
This trial studies how well resistance training with or without creatine monohydrate supplement works in improving body composition and health outcomes in patients with prostate cancer that has spread to other places in the body.
- Conditions
- Fatigue, Metastatic Prostate Carcinoma, Sedentary Lifestyle, Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8
- Trial name
- NCT03987217
- Testing
- Creatine Monohydrate, Exercise Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Utah
Prostate Cancer
Pedometer and Exercise Study in Prostate Cancer Patients With Hormonal Therapy
A randomized clinical trial evaluating the use of a pedometer and brief exercise coaching in prostate cancer patients treated with androgen deprivation therapy.
- Trial name
- NCT00868868
- Where
- Canada
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Groupe de recherche en Urologie de la Mauricie
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of…
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT05946213
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 436 sites in United States, Canada and 3 more
- Volunteers
- 1,500 people
- Sponsor
- NRG Oncology
Prostate Cancer
Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2
Researchers in this study will determine whether providing decision support interventions (DESIs) to men with low risk prostate cancer improves their decision-specific knowledge and alters their treatment decisions.
- Trial name
- NCT01244568
- Testing
- Prostate cancer treatment DESI
- Where
- 2 sites in United States
- Volunteers
- 218 people
- Sponsor
- University of North Carolina, Chapel Hill
Cancer, Breast Cancer
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
- Trial name
- NCT06533059
- Testing
- ALTA2618
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Alterome Therapeutics, Inc.
Prostate Cancer Stage I, Bladder Outlet Obstruction
Transurethral Prostate Enucleation in Surveillance Protocol for Low Risk Prostate Cancer
We will compare oncological and functional outcomes of anatomical endoscopic enucleation of the prostate (AEEP) versus continued medical treatment in low-risk prostate cancer patients for whom an active surveillance protocol was…
- Trial name
- NCT05631080
- Testing
- Anatomical Endoscpic enucleation of the Prostate
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Mansoura University
Glioma, Astrocytoma
Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas
As a part of molecular imaging, many PET tracers have been investigated in this regard. Those include 18F-FDG being glucose analogue, 18F-FLT representing nucleoside metabolism, and 18F-FDOPA, 18F-FET, 11C-MET as amino acids…
- Conditions
- Glioma, Astrocytoma, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT06241391
- Testing
- PSMA PET-CT
- Where
- India
- Volunteers
- 35 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Prostate Cancer
BN83495 in Prostate Cancer
The purpose of the study is to evaluate the pharmacodynamic profile and safety of BN83495 in patients with prostate cancer with disease progression while on androgen ablative therapy
- Trial name
- STX64PC (NCT00790374)
- Testing
- BN83495 (Cohort 1), BN83495 (Cohort 2), BN83495 (Cohort 3)
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Ipsen
Prostatic Neoplasms
Treatment Satisfaction With Ra-223 in Japan
This study aims to answer the research question: Are Japanese bone metastatic CRPC patients satisfied with their Ra-223 treatment, and what factors drive such satisfaction? It also aims to determine patient anxiety regarding…
- Trial name
- NCT03315260
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- Japan
- Volunteers
- 85 people
- Sponsor
- Bayer
Prostate Cancer
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone.
- Trial name
- NCT00021450
- Testing
- bicalutamide, goserelin acetate, adjuvant therapy
- Where
- 20 sites in Belgium, Cyprus and 9 more
- Volunteers
- 819 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may stop the adrenal glands from making androgens.
- Trial name
- NCT00006359
- Testing
- LHRH agonist, antiandrogen, radiation therapy
- Where
- 26 sites in United States
- Volunteers
- 63 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have progressive…
- Trial name
- NCT00005848
- Testing
- chemotherapy, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer
Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
Purpose: The purpose of this clinical trial is to look at the chemotherapy combination of docetaxel and capecitabine in the treatment of newly diagnosed or locally advanced prostate cancer, and to determine if this treatment is…
- Trial name
- NCT00151047
- Testing
- Capecitabine, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer, Thromboembolism
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00014352
- Testing
- docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
This study will evaluate the response rate of MLN8237 in patients with histologically confirmed or clinically suspected metastatic neuroendocrine prostate cancer (NEPC).
- Conditions
- Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer, Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
- Trial name
- NCT01799278
- Testing
- MLN8237
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
The study was a three-arm, active-control, multi-centre, parallel group study.
- Trial name
- NCT00295750
- Testing
- Degarelix, Leuprolide 7.5 mg
- Where
- 35 sites in United States, Canada and 10 more
- Volunteers
- 620 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study
Propranolol, a non-selective adrenergic beta-receptor blocker, is conventionally used to treat arrhythmias. However, recent studies have demonstrated its therapeutic efficacy in breast cancer, prostate cancer, neonatal…
- Trial name
- NCT07311915
- Testing
- Propranolol combined with novel endocrine therapy and androgen deprivation therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhongda Hospital
Metastatic Castration-resistant Prostate Cancer
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once…
- Trial name
- NCT01972217
- Testing
- Olaparib, Abiraterone, Prednisone or prednisolone
- Where
- 41 sites in United States, Belgium and 9 more
- Volunteers
- 158 people
- Sponsor
- AstraZeneca
Prostate Cancer
Health-Related Quality of Life in Gay Men With Localized Prostate Cancer
RATIONALE: Gathering information about prostate cancer, treatment, and quality of life from gay men with prostate cancer may help doctors plan the best treatment.
- Trial name
- NCT00828633
- Where
- 3 sites in United States, Canada
- Volunteers
- 92 people
- Sponsor
- Baylor College of Medicine
Prostate Cancer
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.
- Trial name
- NCT03809078
- Testing
- 68Ga RM2, 68Ga-PSMA-11, Investigational PET scanner coils and software
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Andrei Iagaru